Research Topics
Genomes and Genes | Lap HoSummaryAffiliation: Mount Sinai School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's diseaseJun Wang
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 USA
Mol Neurodegener 6:7. 2011..Proper interpretations of these clinical observations, as well as future development of dimebon in AD treatment are complicated by the lack of concrete information on the mechanisms by which dimebon might benefit AD...- Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathologySteve Pedrini
Farber Institute for the Neurosciences, Jefferson Medical College, Philadelphia PA USA
Mol Neurodegener 4:40. 2009..abstract:.. - Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deteriorationLap Ho
Department of Psychiatry, Mount Sinai School of Medicine, NY, USA
J Alzheimers Dis 16:59-72. 2009..Results from these studies suggest the possibility of developing a "combination" of dietary polyphenolic compounds for AD prevention and/or therapy by modulating multiple Abeta-related mechanisms... 
Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathologyZhong Zhao
Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, NY 10029, USA
FASEB J 19:2081-2. 2005....- Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's diseaseJun Wang
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Pl, New York, NY 10029, USA
FASEB J 20:2313-20. 2006.... - PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementiaWeiping Qin
Department of Psychiatry, Mount Sinai School of Medicine, Bronx, NY, USA
Arch Neurol 66:352-61. 2009.... - Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's diseaseLap Ho
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
FASEB J 18:902-4. 2004.... - Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activityWeiping Qin
Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, New York 10029, USA
J Biol Chem 278:50970-7. 2003.... - Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restrictionWeiping Qin
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
J Biol Chem 281:21745-54. 2006..The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment... - Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's diseaseJun Wang
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
J Neurosci 28:6388-92. 2008..Our study suggests that grape seed-derived polyphenolics may be useful agents to prevent or treat AD... - Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer diseaseJun Wang
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
J Clin Invest 117:3393-402. 2007..These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Abeta-related memory deficits in subjects with AD or in those at high risk of developing AD... - Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deteriorationWeiping Qin
Department of Psychiatry, Mount Sinnai School of Medicine, New York, NY 10029, USA
Ann N Y Acad Sci 1147:335-47. 2008..This study provides a novel metabolic pathway for prevention and/or treatment of AD... - Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesGiulio Maria Pasinetti
Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
J Neurochem 114:1557-68. 2010..In this mini-review article, we discuss the biochemical characterization of GSPE in our laboratory and its potential preventative and therapeutic role in model systems of abnormal tau processing pertinent to PSP and related tauopathies... - Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's diseaseJun Wang
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
FASEB J 19:659-61. 2005.... 
Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's diseaseJun Wang
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
J Alzheimers Dis 22:653-61. 2010....- Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerizationWei Zhao
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
J Alzheimers Dis 16:49-57. 2009..Our studies suggest that certain antihypertensive compounds may prevent AD-type neuropathology through inhibition of Abeta oligomer formation... - GSPE interferes with tau aggregation in vivo: implication for treating tauopathyIsmael Santa-Maria
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurobiol Aging 33:2072-81. 2012..Our studies support further evaluation of GSPE for preventing and/or treating of tauopathies in humans... - Brain-targeted proanthocyanidin metabolites for Alzheimer's disease treatmentJun Wang
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Neurosci 32:5144-50. 2012.... - Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathologyZhongmin Xiang
Neuroinflammation Research Laboratories, Department of Psychiatry, and Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Gene Expr 10:271-8. 2002..Collectively these data suggest that COX-2 influences APP processing and promotes amyloidosis in the brain... - Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in miceLap Ho
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Nutr Neurosci 15:37-45. 2012..As coffee is also a rich source of chlorogenic acids and many bioactive compounds other than caffeine, we hypothesized that decaffeinated coffee drinks may exert beneficial effects on the brain... - A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosisZhong Zhao
Neuroinflammation Research Laboratories, Department of Psychiatry, USA
BMC Neurosci 7:29. 2006..The cause of neuronal death in amyotrophic lateral sclerosis (ALS) is uncertain but mitochondrial dysfunction may play an important role. Ketones promote mitochondrial energy production and membrane stabilization... - S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10Weiping Qin
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
PLoS ONE 4:e4183. 2009.... - Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implicationsGiulio Maria Pasinetti
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
Interdiscip Top Gerontol 35:159-75. 2007.... - Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathologyZhongmin Xiang
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
Neurobiol Aging 23:327-34. 2002.... - Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementiaZhongmin Xiang
Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, 10029-6574, USA
Dis Markers 22:95-102. 2006..These results suggest that microglia activation increases with the progression of AD, with the increase varying depending on the involved brain region... - Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathiesLap Ho
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
J Alzheimers Dis 16:433-9. 2009.... - The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathologyJun Wang
Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Biochim Biophys Acta 1804:1690-4. 2010..We will discuss Sirt1 as a potential novel target, in addition to the development of Sirt1 activators for the prevention and treatment of Alzheimer's disease... - Carvedilol as a potential novel agent for the treatment of Alzheimer's diseaseJun Wang
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurobiol Aging 32:2321.e1-12. 2011..Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD... - Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applicationsLap Ho
Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, and Center of Excellence in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1137, New York, NY 10029, USA
Exp Gerontol 45:15-22. 2010..The availability of biomarkers that promote early disease diagnosis, particularly among asymptomatic patients, will lead to the application of personalized medicine in AD... - Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?Lap Ho
Department of Psychiatry, The Mount Sinai School of Medicine, Neuroinflammation Research Laboratories, New York, New York 10029, USA
CNS Drugs 20:85-98. 2006.... - Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult micePaul H Wen
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
Neurobiol Dis 10:8-19. 2002..These studies suggest that PS-1 plays a role in regulating neurogenesis in adult hippocampus and that FAD mutants may have deleterious properties independent of their effects on amyloid deposition... - Caspase gene expression in the brain as a function of the clinical progression of Alzheimer diseasePatrick N Pompl
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
Arch Neurol 60:369-76. 2003..These data have relevance to potential therapeutic interventions for AD using selective caspase inhibitors... - From proteomics to biomarker discovery in Alzheimer's diseaseLap Ho
Neuroinflammation Research Laboratories of the Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Brain Res Brain Res Rev 48:360-9. 2005.... - Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease casesLap Ho
Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA
Int J Alzheimers Dis 2012:321280. 2012..Outcomes from our study support the development of insulin-sensitizing therapeutic strategies to stimulate downstream IR signaling in nondiabetic AD cases... - Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's diseaseLap Ho
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
J Alzheimers Dis 31:301-13. 2012..Induction of MCP-1 in response to TBI might be a potential predisposing factor that may increase the risk for development of Alzheimer's disease... - Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenolsHanna Ksiezak-Reding
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Neurobiol Aging 33:1427-39. 2012..Collectively, our results suggest that GSPE has a significant potential for therapeutic development by neutralizing phospho-epitopes and disrupting fibrillary conformation leading to disintegration of PHFs... - Polyphenolic compounds for treating neurodegenerative disorders involving protein misfoldingLap Ho
Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Expert Rev Proteomics 7:579-89. 2010..Collectively, available information supports continued development of the GSPE for treating a variety of neurodegenerative disorders involving misfolded protein-mediated neuropathologic mechanisms... - Immunomodulation with glatiramer acetate prevents long-term inflammatory painNaresh Sharma
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
Int J Neurosci 118:433-53. 2008..This study is consistent with the hypothesis that a novel mechanism through which GA immunization therapy may beneficially influence long-term allodynia and hyperalgesia is through central regulation of fractalkine-mediated responses... - Personalized medicine in traumatic brain injuryGiulio Maria Pasinetti
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1137, New York, NY 10029, USA
Psychiatr Clin North Am 33:905-13. 2010..It is possible that the availability of TBI biomarkers may provide potential elements with clinical relevance to prevention, prognosis, and treatment of postconcussive disorders... - Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disordersGiulio Maria Pasinetti
Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, 1498 Madison Avenue, New York, NY 10029, USA
Exp Neurol 232:1-6. 2011..study and discusses the further prospects of resveratrol and other polyphenols, including novel grape-derived polyphenols, in the treatment of HD and other neurodegenerative disorders... - Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementiaGiulio Maria Pasinetti
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
Int J Alzheimers Dis 2011:806293. 2011..We further discuss how the consumption of certain foods or food components can help to reduce one's risk for Alzheimer's disease and may possibly be developed as a therapeutic agent... - Expression profile of genes associated with antimetastatic gene: nm23-mediated metastasis inhibition in breast carcinoma cellsHui Zhao
Department of Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
Int J Cancer 109:65-70. 2004.... - Amyloid immunization in Alzheimer's disease: do we promote amyloid scavenging at the cost of inflammatory degeneration?Giulio Maria Pasinetti
Department of Psychiatry, Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, NY 10089, USA
Neurobiol Aging 23:665-6. 2002 - Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2Lauren Spielman
Neuroinflammation Research Laboratories, Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
Acta Neuropathol 103:157-62. 2002..Because there is extensive evidence that C1q and other complement components are involved in Alzheimer's disease (AD) neurodegeneration, this study advances our understanding of the apparent benefits of COX-2 inhibition in AD...